The Hormone Study (MAD)

The Hormone Study is exploring a new potential treatment for hypoparathyroidism—a rare endocrine condition characterized by low or insufficient levels of parathyroid hormone (PTH). PTH is essential for regulating calcium and phosphorus through direct actions on bone and kidney.

The study drug, administered via an oral capsule, aims to provide a physiologic replacement for the lack of PTH, addressing the limitations of conventional treatments that rely on calcium supplements and active vitamin D. These conventional treatments do not fully address the underlying hormone deficiency and can have side effects that impact patients’ quality of life.

This study is important because it seeks to meet the unmet medical need for treatments that lack the side effects associated with long-term conventional therapy for hypoparathyroidism.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!